Comparative Pharmacology
Head-to-head clinical analysis: GO EVAC versus PLENVU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GO EVAC versus PLENVU.
GO-EVAC vs PLENVU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promotes gastrointestinal motility by acting as a stimulant laxative, likely through direct irritation of the colonic mucosa and possibly via local effects on enteric neurons.
PLENVU is an osmotic laxative that induces bowel cleansing by causing water retention in the colon, leading to increased intraluminal pressure and stimulation of peristalsis. Its components (polyethylene glycol 3350, sodium ascorbate, ascorbic acid, sodium sulfate) act synergistically to produce a cathartic effect.
10 mg orally once daily, with or without food.
2 sachets (each containing ascorbic acid 4.7g, macrogol 3350 52.5g, sodium ascorbate 5.9g, sodium sulfate 3.75g) dissolved in water to a total volume of 500mL, administered orally as a split-dose regimen: first dose (2 sachets in 500mL water) at 6-9 pm on the day before colonoscopy, followed by additional 500mL of clear fluids; second dose (2 sachets in 500mL water) on the morning of colonoscopy, completed at least 2 hours before the procedure, followed by additional 500mL of clear fluids.
None Documented
None Documented
4.5-6 hours in healthy volunteers; prolonged to 10-14 hours in elderly patients and those with moderate renal impairment (CrCl 30-50 mL/min).
Not applicable (non-absorbed agent); systemic absorption is minimal, so no terminal half-life is defined.
Primarily renal; approximately 60% eliminated unchanged in urine within 24 hours, with 20% as metabolites. Biliary/fecal excretion accounts for 15-20%, and the remainder is metabolized via glucuronidation.
Primarily fecal (90-95%) as unabsorbed drug; renal excretion is negligible (<1%).
Category C
Category C
Osmotic Laxative
Osmotic Laxative